{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,25]],"date-time":"2024-12-25T17:10:12Z","timestamp":1735146612561,"version":"3.32.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,25]]},"DOI":"10.7759\/cureus.76375","type":"journal-article","created":{"date-parts":[[2024,12,25]],"date-time":"2024-12-25T16:39:39Z","timestamp":1735144779000},"source":"Crossref","is-referenced-by-count":0,"title":["A Case of Lepromatous Leprosy Presenting With Multiple Morphologies in Philadelphia"],"prefix":"10.7759","author":[{"given":"Margaret A","family":"O'Brien","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan","family":"Hyde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvia","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Global Leprosy Strategy 2016-2020: Accelerating towards a leprosy-free world","year":"2016","unstructured":"Global leprosy strategy 2016-2020. accelerating towards a leprosy-free world. WHO Regional Office for South-East Asia, India; 2016. http:\/\/apps.who.int\/iris\/handle\/10665\/208824."},{"key":"ref2","article-title":"Global leprosy (Hansen disease) update, 2020: impact of COVID-19 on the global leprosy control","volume":"96","year":"2021","unstructured":"Global leprosy (Hansen disease) update, 2020. impact of COVID-19 on the global leprosy control. Wkly Epidemiol Rec. 2021, 96:421-44.","journal-title":"Wkly Epidemiol Rec"},{"key":"ref3","unstructured":"Number of new leprosy cases. (2024). Accessed. October 13, 2024: https:\/\/www.who.int\/data\/gho\/data\/indicators\/indicator-details\/GHO\/number-of-new-leprosy-cases."},{"key":"ref4","unstructured":"Hansen's disease data & statistics. (2015). Accessed. May 2, 2022: https:\/\/www.hrsa.gov\/hansens-disease\/data-and-statistics."},{"key":"ref5","unstructured":"Penn doctors honored as 'Patient Care Heroes' for treating rare case of leprosy disease. (2019). Accessed. May 2, 2022: https:\/\/www.thedp.com\/article\/2019\/03\/leprosy-cure-penn-medicine-patient-care-heroes-dermatology."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.12.080","article-title":"Leprosy: clinical aspects and diagnostic techniques","volume":"83","author":"Maymone MB","year":"2020","unstructured":"Maymone MB, Laughter M, Venkatesh S, et al.. Leprosy: clinical aspects and diagnostic techniques. J Am Acad Dermatol. 2020, 83:1-14. 10.1016\/j.jaad.2019.12.080","journal-title":"J Am Acad Dermatol"},{"key":"ref7","unstructured":"Control of neglected tropical diseases. (2022). Accessed. May 2, 2022: https:\/\/www.who.int\/teams\/control-of-neglected-tropical-diseases\/leprosy\/treatment."},{"key":"ref8","unstructured":"NHDP guide to the management of Hansen's disease. (2017). Accessed. August 3, 2022: http:\/\/www.hrsa.gov\/sites\/default\/files\/hrsa\/hansens-disease\/hansens-disease-guide-management.pdf."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.159929","article-title":"A randomized controlled trial to compare cure and relapse rate of paucibacillary multidrug therapy with monthly rifampicin, ofloxacin, and minocycline among paucibacillary leprosy patients in Agra District, India","volume":"81","author":"Kumar A","year":"2015","unstructured":"Kumar A, Girdhar A, Girdhar BK. A randomized controlled trial to compare cure and relapse rate of paucibacillary multidrug therapy with monthly rifampicin, ofloxacin, and minocycline among paucibacillary leprosy patients in Agra District, India. Indian J Dermatol Venereol Leprol. 2015, 81:356-62. 10.4103\/0378-6323.159929","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"ref10","doi-asserted-by":"crossref","DOI":"10.4269\/ajtmh.2004.70.197","article-title":"Parallel assessment of 24 monthly doses of rifampin, ofloxacin, and minocycline versus two years of World Health Organization multi-drug therapy for multi-bacillary leprosy","volume":"70","author":"Villahermosa LG","year":"2004","unstructured":"Villahermosa LG, Fajardo TT Jr, Abalos RM, et al.. Parallel assessment of 24 monthly doses of rifampin, ofloxacin, and minocycline versus two years of World Health Organization multi-drug therapy for multi-bacillary leprosy. Am J Trop Med Hyg. 2004, 70:197-200.","journal-title":"Am J Trop Med Hyg"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5154.108029","article-title":"Fixed-duration therapy in leprosy: limitations and opportunities","volume":"58","author":"Malathi M","year":"2013","unstructured":"Malathi M, Thappa DM. Fixed-duration therapy in leprosy: limitations and opportunities. Indian J Dermatol. 2013, 58:93-100. 10.4103\/0019-5154.108029","journal-title":"Indian J Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/112680-a-case-of-lepromatous-leprosy-presenting-with-multiple-morphologies-in-philadelphia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,25]],"date-time":"2024-12-25T16:39:42Z","timestamp":1735144782000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/112680-a-case-of-lepromatous-leprosy-presenting-with-multiple-morphologies-in-philadelphia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,25]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.76375","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,25]]}}}